The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September. The drug has a novel mechanism of action ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recently approved xanomeline and trospium chloride (Cobenfy ...

Related: Bristol Myers Squibb's stock jumps on schizophrenia-drug approval "While we are disappointed ... Cobenfy "represents the first new class of medicine in several decades," the Princeton ...

Shares of rival Bristol Myers, which received U.S. approval for its schizophrenia treatment in September, surged 10.2% to $59.66. Bristol and AbbVie's drug belong to a new class of treatments that ...